VERISOL Clinical Studies

This graph demonstrates the efficiency of VERISOL® Bioactive Collagen Peptides®.

"Skin wrinkles were objectively measured in all subjects, before stating the treatment, after 4 and 8 weeks as well as 4 weeks after the last intake (4-week regression phase)."

 

  • Two studies have been performed to establish the efficiency (2011 & 2012).

  • Participants included 180 women between the ages of 35 and 60 with normal skin.

  • Each participant recieved either VERISOL or a placebo.

  • Test periods lasted 8 weeks with measurements after 4 & 8 weeks, followed by a 4-week wash out.

  • Aging parameters include skin elasticity and wrinkle volume.

 

Clinical Study Measurements:

 

  • Eye wrinkle volume decreased by 20% on average (with the HIGHEST wrinkle reduction at 49%)

  • Procollagen Type I content increased by 65%

  • Elastin content increased by 18%

  • Eye wrinkle volume maintained a decreased amount of 18% 4 weeks after the last in-take.

* 8 weeks clinical study of daily oral VERISOL® Treatment (2500mg) in comparison to placebo administration. Skin Pharmacology and Physiology Vol. 27, No. 1,1014 Issue Release Date: August 2013. Department of Dermatology, University of Kiel, and CRI, Collagen Research Institute, Kiel and Skin Ingestion and Technology, Hamburg, Germany.

 

VERISOL® Bioactive Collagen Peptides® are registered trademarks of GELITA AG, Germany.

 

  • Helps to increase joint mobility

  • Promotes optimal physical performance

  • Supports cartilage tissue regeneration

+Joints

FORTIGEL Clinical Studies

FORTIGEL regenerates cartilage tissue in humans *24 week study design of FORTIGEL treatment in comparison of Placebo administration of proteoglycan content in knee cartilage. Harvard/Tufts Study, USA (McAindon,2009).